Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00164502 · ClinicalTrials.gov registry record · Phase 2

Limb Loss Self-Management Program

A Phase 2 study of Congenital or Acquired Limb Deficiency, sponsored by Centers for Disease Control and Prevention.

Completed
Registry status
Phase 2
Development phase
500
Enrollment target
1
Study location

NCT00164502: Completed Phase 2 study of Congenital or Acquired Limb Deficiency, sponsored by Centers for Disease Control and Prevention.

NCT00164502 is a Phase 2 study of Congenital or Acquired Limb Deficiency that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 500 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00164502, a Phase 2 study of Congenital or Acquired Limb Deficiency, has completed, sponsored by Centers for Disease Control and Prevention.

COMPLETED
Registry status
Phase 2
Development phase
500 participants
Enrollment target
1
Study location

Study Summary

The goal of the project is to develop and test the efficacy of a community-based self-management intervention for reducing pain, depression, and improving self-efficacy and function in person with limb loss

Interventions

  • BEHAVIORAL Community-based eight session group self-management program

Study Locations (1)

Washington

  • Puget Sound Health Services - Seattle

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2003-10
Est. Completion 2005-06
Phase Phase 2

What the finished NCT00164502 record still lists

NCT00164502 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher).

The record links to 1 condition, with Congenital or Acquired Limb Deficiency appearing as the primary indexed condition, and to 1 intervention - of which Community-based eight session group self-management program is the first listed.

NCT00164502 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT00164502 about?

NCT00164502 is a clinical study titled "Limb Loss Self-Management Program". The goal of the project is to develop and test the efficacy of a community-based self-management intervention for reducing pain, depression, and improving self-efficacy and function in person with limb loss

What is the current status of trial NCT00164502?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2003-10. Estimated completion is 2005-06.

What conditions does trial NCT00164502 study?

This clinical trial studies the following conditions: Congenital or Acquired Limb Deficiency.

What interventions are being tested in trial NCT00164502?

The interventions under investigation include: Community-based eight session group self-management program (BEHAVIORAL).

Who is sponsoring clinical trial NCT00164502?

This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00164502 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

How this trial's enrollment target compares

Where NCT00164502's enrollment target sits among peer trials

500 70th of 2000 higher than 1,927 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00164502, the US trial registry maintained by the National Library of Medicine. NCT00164502 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.